return of urinary continence, and recovery of sexual function that constitute the RARP 00 trifecta 00 . A method to quantifying RARP outcome was developed in Europe that classifies survival (S), continence (C), and potency (P). The SCP mimics the TNM system used for staging. We sought to validate SCP in a large cohort of Americans followed for more than 5 years after RARP.
return of urinary continence, and recovery of sexual function that constitute the RARP 00 trifecta 00 . A method to quantifying RARP outcome was developed in Europe that classifies survival (S), continence (C), and potency (P). The SCP mimics the TNM system used for staging. We sought to validate SCP in a large cohort of Americans followed for more than 5 years after RARP.
METHODS: A retrospective review of prospectively collected data from 800 men who underwent RARP from Jan 2006 to Dec 2011 was performed. Total of 637 men were used for analysis after applying inclusion and exclusion criteria. NCCN biochemical failure was used as a proxy for oncologic outcome (S). The UCLA-Prostate Cancer Index Urinary Function and Sexual Function Questionnaires were used to evaluate continence (C) and potency (P), respectively. Continence was refined further by querying medical records for use of a security pad.
RESULTS: The 5-and 10-year biochemical progression-free survival rates were 93% (95% CI: 0.90-0.95) and 73% (95% CI: 0.67-0.79), respectively. At last follow up, 502 (79%) patients used no pads (C0), 70 (11%) patients used one security pad (C1), 63 (9.8%) patients used one or more pads routinely (C2), and 2 (0.2%) patients were incontinent before RARP (Cx). Of the 522 (82%) patients who had bilateral nerve-sparing RARP, 128 (24.5%) patients were fully potent without use of aids (P0), 74 (14.2%) patients were potent with PDE-5 inhibitor (P1), 320 (61.3%) patients experienced erectile dysfunction (P2). 115 (18%) patients were impotent preoperatively or did not undergo bilateral nerve sparing (Px). In patients preoperatively continent and potent who underwent bilateral nerve preservation and did not require adjuvant radiation therapy, oncologic and functional perfection (S0C0P0) was achieved in 58 (45%) patients. Oncologic and continence perfection (S0C0) was achieved in 92 (80%) of patients for whom potency was not recoverable (Px).
CONCLUSIONS: SCP classification offers a tool for objective assessment of oncologic and functional outcome after RARP.
Source of Funding: none

MP93-12 PROSTATE CANCER IN MEN YOUNGER THAN 55: RATES OF FUNCTIONAL RECOVERY POST-ROBOTIC ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY
Tracey Woodlief*, Hariharan Ganapathi, Gabriel Ogaya-Pinies, Eduardo Hernandez, Travis Rogers, Vipul Patel, Celebration, FL INTRODUCTION AND OBJECTIVES: Time to and overall likelihood to achieve recovery of functional outcomes within one year of undergoing a radical prostatectomy are of high importance to many patients post-RP, with return of continence and potency being at the top of the list. Age at surgery, comorbidities, rehabilitation compliance, pre-operative-SHIM and degree of nerve spare during surgery encompass some of the main impactors of recovery outcomes and therefore are utilized in the current retrospective analysis to further subdivided men 55 yo with a minimal follow-up of 1 year.
METHODS: In a retrospective analysis of our IRB approved database between January 2008 and January 2016, 1411 patients who underwent RARP were 55 years old (yo) or less with an average age of 51 AE 0.1 yo (range 32 to 55 yo). Within this subgroup, 1,087 patients had a minimum of one year of follow-up and therefore were included in this analysis of functional outcomes. Date of return of continence and potency were both self-reported. Return of continence was defined as the use of no-pads each day, while return of potency was defined as the ability to achieve an erection and to have successful intercourse more than 50% of the time. All statistical analysis was completed in JMP 12 utilizing a Tukey all pairs test. RESULTS: When subdivided by age, while there was no significant difference in the percentage of men in each age subgroup in return to continence, there was a significant increase in the number of days to return to continence in Group 3 (65 AE 4) versus Group 1 (45 AE 3). While, the percentage of men and the number of days to potency in Group 3 (82%; 159 AE 11) was significantly higher than Group 1 (91%; 122 AE 16). Next, when subdivided by both age and pre-op SHIM, there was no significant difference in the number of days to continence or percentage of patients with return within one year. Lastly when subdivided by all here factors (age, pre-op SHIM, and NS), there were no significant differences in the number of days or percentage of patients whom achieved continence within one year. While, group 3 was most effects by both degree of nerve spare and pre-operative SHIM, with the main significant difference being in Group 3b when subdivided into FNS versus PNS.
CONCLUSIONS: Age, pre-operative SHIM and degree of nerve spare all have a significant effect on the return of continence and potency in men ¼ 55yo, thereby reinforcing the role of each in return of functional outcomes. Increases in age have a significant impact on recovery of potency. Younger patients with a pre-operative SHIM >20 who underwent a FNS report the fastest return to both continence and potency.
Source of Funding: None
MP93-13 EXPLORING POSITIVE SURGICAL MARGINS AFTER MINIMALLY INVASIVE RADICAL PROSTATECTOMY: DOES BODY HABITUS REALLY MAKE A DIFFERENCE?
Simone Albisinni*, Julien Grosman, Bruxelles, Belgium; Fouad Aoun, bruxelles, Belgium; Thierry Quackels, Bruxelles, Belgium; Alexandre Peltier, Roland van Velthoven, bruxelles, Belgium; Thierry Roumegu ere, Bruxelles, Belgium INTRODUCTION AND OBJECTIVES: Positive surgical margins (PSMs) at radical prostatectomy (RP) are generally recognized as a surrogate of poor or difficult dissection of the prostatic gland. In open RP cohorts, obesity seems to be associated to an increased risk of PSMs, probably due to the technical challenge that obese men pose to surgical access. Minimally invasive RP has been claimed to possibly reduce PSM rate. Aim of the study was to explore the impact of obesity and body habitus on PSM risk and their localisation during laparoscopic and robotic-assisted RP.
METHODS: We reviewed 539 prospectively enrolled patients undergoing laparoscopic and robotic-assisted RP with pT2 prostate cancer. The outcome measured was rate of PSM according to the BMI and surgical approach (laparoscopic vs robotic-assisted). BMI groups were compared using Kruskall-wallis or ?2 test, as appropriate. Uni-and multivariate logistic regression models were constructed to assess the impact of BMI and surgical technique on PSM risk. RESULTS: Overall, 127 (24%) of men had PSMs detected at final specimen evaluation. Mean PSM length was 3.9AE3.4mm, and 30 (6%) men presented significant margins !4mm. Analysing the rate of PSMs across BMI categories, no significant association between increased BMI and PSM was detected (all p>0.48)(table 1). On uni-and multivariate logistic regression BMI was not a statistically significant risk factor for PSM (p¼0.14), nor was the minimally invasive technique (laparoscopic vs robotic-assisted) (p¼0.54).
CONCLUSIONS: In this study obese men do not appear to have a significant increase in risk of PSMs at RP compared to lean and overweight men when operated by a minimally invasive approach. The magnified vision and increased access to the pelvis allowed by a laparoscopic and robotic-assisted approach may be accountable for our findings. Larger studies are needed to validate our results. Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 THE JOURNAL OF UROLOGY â e1241
